Understanding and targeting gut-brain communication in depression

The gut microbiome has been implicated in depression through its interactions with host physiology and the brain. Butyrate, a microbial metabolite with immunomodulatory and neurobiological effects, may represent a potential mediator of gut–brain communication and therapeutic target. The evidence for these relationships was examined across systematic reviews, population-based analyses, and translational research.
Preclinical studies suggest that butyrate may influence depressive-like behavior through anti-inflammatory, neuroplastic, and epigenetic mechanisms, whereas clinical evidence remains scarce and inconclusive. In the HELIUS cohort, no conclusive associations were found between fecal short-chain fatty acids (SCFAs), predicted microbial SCFA pathways, and depressive symptoms. Similarly, childhood maltreatment showed no single pattern with adult gut microbiota composition or predicted function among 5,749 participants, suggesting that its long-term effects may involve broader biopsychosocial pathways.
The clinical potential of butyrate is being investigated in the BUTY-trial, a placebo-controlled pilot study of adjunctive tributyrin supplementation in patients with major depressive disorder. Preliminary findings indicate good adherence among enrolled participants but substantial recruitment challenges. Complementary preclinical research investigates tributyrin in a mouse model combining early-life and adolescent stress, incorporating both sexes and multiple behavioral and physiological outcomes. A systematic review of neuromodulation studies further suggests that interventions targeting brain activity may influence bacterial abundances, although findings remain inconclusive.
Further mechanistic and translational research is needed to clarify the role of microbial metabolites, particularly butyrate, in the microbiota–gut–brain axis and their potential relevance to depression.